Pfizer: Unclear whether COVID-19 will be transmitted after vaccination
Pfizer: Unclear whether COVID-19 will be transmitted after vaccination
Pfizer: Unclear whether COVID-19 will be transmitted after vaccination. Overseas Network, December 4th. Pfizer CEO Albert Bourla said on the 3rd local time that it is still unclear whether people vaccinated with Pfizer’s COVID-19 vaccine can still spread the virus.
In an interview with NBC, Burla said that whether the new coronavirus will spread after vaccination is still a matter of long-term observation. He currently knows nothing about it. Burla said that he believes that participants who have only received the placebo vaccine trial will also be vaccinated.
Burla said: “This is a moral and ethical dilemma and obligation. I believe that in discussions with regulatory agencies, we should find a way instead of vaccinating all placebo participants sooner or later.”
According to reports, Pfizer has asked the US Food and Drug Administration (FDA) to obtain emergency use authorization for its vaccine. FDA consultants will meet on December 10 local time to discuss the application. In addition, a spokesperson for the British Ministry of Health and Social Care said on the 2nd that the government has accepted the recommendations of the Drug and Medical Products Regulatory Agency to approve the use of Pfizer and BioNTech’s COVID-19 vaccine. The vaccine will be available throughout the UK starting next week, and the UK has therefore become the first country in the world to approve the use of the vaccine.
However, Dr. Paul Offit (Paul Offit), director of the Vaccine Education Center at the Children’s Hospital of Philadelphia and member of the FDA Vaccine Advisory Committee, said that there are still many unresolved problems with this vaccine. Offit said: “We have to answer one million questions to ensure that we know exactly the safety and efficacy of the vaccine. Is this vaccine effective for people over 65? Is it in different ethnic groups and ethnic groups? Equally effective? Is it effective for people with various diseases?”
In early November, Pfizer said that the results of a large-scale study showed that the COVID-19 vaccine developed by Pfizer prevented 90% of COVID-19 infections. In several releases in the following month, Pfizer adjusted the effectiveness of its COVID-19 vaccine to 95% and stated that it has met the requirements for emergency use authorization and will submit an application to the regulatory authority within a few days.
However, Pfizer’s COVID-19 vaccine adopts a new technology that has never been used in large-scale human vaccination before. Experts warn in this regard that people still know little about its safety, effective time and beneficiary population.
